CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

by Ranjan Chrisanthar, Stian Knappskog, Erik Løkkevik, Gun Anker, Bjørn Østenstad, Steinar Lundgren, Elisabet O Berge, Terje Risberg, Ingvil Mjaaland, Lovise Maehle, Lars Fredrik Engebretsen, Johan Richard Lillehaug, Per Eystein Lønning
Published 2008-01-01